Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Empagliflozin for the Treatment of Postprandial Hypoglycemia

NCT05036317 is registered in ClinicalTrials.gov with University Hospital, Basel, Switzerland as lead sponsor.

NCT NCT05036317
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05036317 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Empagliflozin for the Treatment of Postprandial Hypoglycemia
Lead sponsor
University Hospital, Basel, Switzerland
Phase
Phase 3
Overall status
Terminated
Start date
March 11, 2022
Completion date
August 5, 2024
Enrollment
40 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

postprandial hypoglycemia